Effect of Cu supplementation on genomic instability in chemically-induced mammary carcinogenesis in the rat

Journal of Biomedical Science

Research

Barbara Bobrowska¹  Dorota Skrajnowska¹  Andrzej Tokarz¹ 

[1] Department of Bromatology, Medical University of Warsaw, Banacha 1, 02-097, Warsaw, Poland;

关键词: Resveratrol;    Standard Diet;    Microsatellite Instability;    Mammary Cancer;    Mammary Carcinogenesis;   

DOI  :  10.1186/1423-0127-18-95

 received in 2011-06-20, accepted in 2011-12-22,  发布年份 2011

来源: Springer

【 摘 要 】

BackroundThe aim of the present study was to assess the effect of dietary supplementation (copper or copper and resveratrol) on the intensity of carcinogenesis and the frequency of microsatellite instability in a widely used model of mammary carcinogenesis induced in the rat by treatment with 7,12-dimethylbenz[a]anthracene (DMBA).MethodsDNA was extracted from rat mammary cancers and normal tisues, amplified by PCR, using different polymorphic DNA markers and the reaction products were analyzed for microsatellite instability.ResultsIt was found that irrespectively of the applied diet there was no inhibition of mammary carcinogenesis in the rats due to DMBA. Besides, in the groups supplemented with Cu (II) or Cu (II) and resveratrol the tumor formation was clearly accelerated. Unlike the animals that were fed with standard diet, the supplemented rats were characterized by the loss of heterozygosity of microsatellite D3Mgh9 in cancer tumors (by respectively 50 and 40%). When the animals received Cu (II) and resveratrol supplemented diet the occurrence of genomic instability was additionally found in their livers in the case of microsatellite D1Mgh6 (which was stable in the animals without dietary supplementation).ConclusionsIdentification of the underlying mechanisms by which dietary factors affect genomic stability might prove useful in the treatment of mammary cancer as well as in the incorporation of dietary factors into mammary cancer prevention strategies.

【 授权许可】

CC BY   
© Bobrowska et al; licensee BioMed Central Ltd. 2011